Emcure Pharmaceuticals Reports Strong Q2 FY27 Results and Raises Full-Year Revenue Guidance
Emcure Pharmaceuticals Ltd · Transcript · 06 Nov 2026, 10:17 pm
Emcure Pharmaceuticals Reports Strong Q2 FY27 Results and Raises Full-Year Revenue Guidance Emcure Pharmaceuticals reported Q2 FY27 revenue growth of 24.3% YoY to INR2,820 crores, with EBITDA rising 31% YoY to INR575 crores as margins expanded 100 bps YoY to 20.4%. PAT increased 29% YoY to INR325 crores. Growth was driven by international markets, up 34.5% YoY to INR1,665 crores (59% of revenue), while India grew 12% YoY to INR1,155 crores. Following strong 1H performance, management raised full-year FY27 revenue guidance to above 20% YoY and expects EBITDA margin improvement at the upper end of 75–100 bps.
Original exchange filing (PDF)
More announcements from Emcure Pharmaceuticals Ltd
- Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026 · 15 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026 · 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026 · 06 Nov 2026
- Audio recording of Earnings Call - Q2 FY27 · 04 Nov 2026
- Presentation on Unaudited Financial Results for the quarter ended September 30, 2026 · 03 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026 · 03 Nov 2026
- Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 03 Nov 2026
- For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026. · 03 Nov 2026
